Anthos Changing Course With Factor XIa Inhibitor, Targeting Atrial Fibrillation Patients First
Executive Summary
With a Phase II study stopped for efficacy in bleeding reduction, Anthos hopes to bring abelacimab, a dual Factor XI/XIa inhibitor to market to prevent strokes in a-fib patients and to treat cancer patients with thrombosis.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Novartis gives back Beigene PD-1; BMS revs R&D engine; Anthos changes course for Factor XI asset; the non-incretin pipeline for obesity; and a look at Q2’s top-selling drugs.
BMS Speeding Six More Programs Into Late-Stage R&D
With big losses of exclusivity later in this decade, Bristol is looking to boost the number of products in its portfolio by 2030 even beyond the $35bn-plus in new revenue it already expects to bring in.
Bayer Goes All In With Asundexian And Pulls Two Other Factor XIa Projects
Despite promising mid-stage data for the Ionis-partnered fesomersen and osocimab, licensed from Aronora, the German major has plumped for asundexian as the priority compound for its Factor XIa efforts.